Results 71 to 80 of about 5,062,841 (308)

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Wanted: Affordable medicines for all

Africa Renewal, 2017
Pneumonia, an acute infection of the lungs, is the biggest killer of children worldwide even though it is treatable and easily preventable with vaccines.
openaire   +2 more sources

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Molecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O. Estevam, Jean‐Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S. Fraser, Martin Figeac, Alexis B. Cortot, Etienne Rouleau, David Tulasne   +14 more
wiley   +1 more source

Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness

Critical Care, 2017
All of medicine aspires to be precise, where a greater understanding of individual data will lead to personalized treatment and improved outcomes. Prompted by specific examples in oncology, the field of critical care may be tempted to envision that ...
Christopher W. Seymour, Hernando Gomez, Chung-Chou H. Chang, Gilles Clermont, John A. Kellum, Jason Kennedy, Sachin Yende, Derek C. Angus   +7 more
doaj   +1 more source

Not All Inhaled Medicines Are Equal

Annals of the American Thoracic Society, 2022
Roy A. Pleasants, Stephen L. Tilley
openaire   +2 more sources

Medicines for all, not just the rich

Bulletin of the World Health Organization, 2001
March brought bad news for the HIV virus, but good news for HIV/AIDS patients, particularly those in poor countries. In the second week of the month, Merck and Co., a leading US pharmaceutical manufacturer, announced it would slash the prices of two of its antiretroviral drugs, indivar (Crixivan) and efavirenz (Stocrin), by 90% to US$ 600 and US$ 500 ...
openaire   +3 more sources

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

«Es ist nicht alles Gold, was glänzt!» / Wie hilft uns die «Evidence-based Medicine»? [PDF]

, 2001

openalex   +3 more sources

Designing a summative assessment blueprint in community medicine: an expert consensus approach at All India Institute of Medical Sciences

BMC Medical Education
Background Despite the increasing integration of competency-based education in medicine, there remains a significant gap in effectively assessing educational outcomes, underscoring the urgent need for designed assessment blueprints that accurately ...
Pragya Kumar, Neha Chaudhary, Arun Mahadeo Kokane, Forhad Zaman, Bhushan Kamble, Kishore Yadav, Vinoth Kumar Kalidoss, Govindrao Narsingrao Kusneniwar, Prasanna Thirunavukkarasu, Manoj Kumar Gupta, Sanjeev Kumar, Richa, Bijit Biswas, Deepti Dabar, Anjan Kumar Giri, Bijaya Nanda Naik, Santosh Kumar Nirala, Santosh Kumar, Rajeev Aravindakshan, Sanjay Pandey, Sathiyanarayanan S, Swayam Pragyan Parida, Alok Ranjan, Abhisek Mishra, Saket Shekhar, Abhishek Kumar, Pallavi Lohani, Arshad Ayub, Swati Shikha, Geetika Singh, Deepika Agrawal, Shamshad Ahmad   +31 more
doaj   +1 more source

Where have all the medicines gone? [PDF]

Archives of Disease in Childhood, 2016
“The test of morality of a society is what it does for its children” is a famous quote from the German philosopher, Dietrich Bonhoeffer. Yet we struggle to deliver appropriate medicines to our children on so many levels. With a lack of studies being performed on both the medicines and the formulations that we are using, it is a wonder that we ever have
openaire   +2 more sources